Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Doig

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Critical Care Medicine|October 11, 2005
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatmentJean-Louis Vincent, Gordon R Bernard, Richard Beale, et al.
BMC Health Services Research|August 15, 2024
Impact of restricted family presence during the COVID-19 pandemic on critically ill patients, families, and critical care clinicians: a qualitative systematic reviewKarla D Krewulak, Natalia Jaworska, Laurie Lee, et al.
Critical Care Medicine|January 11, 2005
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levelsEdward A Panacek, John C Marshall, Timothy E Albertson, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2011
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trialRichard G Wunderink, Pierre-François Laterre, Bruno Francois, et al.
JAMA|July 10, 2003
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trialEdward Abraham, Konrad Reinhart, Steven Opal, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Critical Care Medicine|October 11, 2005
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatmentJean-Louis Vincent, Gordon R Bernard, Richard Beale, et al.
BMC Health Services Research|August 15, 2024
Impact of restricted family presence during the COVID-19 pandemic on critically ill patients, families, and critical care clinicians: a qualitative systematic reviewKarla D Krewulak, Natalia Jaworska, Laurie Lee, et al.
Critical Care Medicine|January 11, 2005
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levelsEdward A Panacek, John C Marshall, Timothy E Albertson, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2011
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trialRichard G Wunderink, Pierre-François Laterre, Bruno Francois, et al.
JAMA|July 10, 2003
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trialEdward Abraham, Konrad Reinhart, Steven Opal, et al.
Pageof 5